Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy

NCT01987817 is registered in ClinicalTrials.gov with Aimmune Therapeutics, Inc. as lead sponsor.

NCT NCT01987817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01987817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy
Lead sponsor
Aimmune Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 6, 2014
Completion date
January 7, 2015
Enrollment
56 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy